In a study of 444 patients, the firm and its collaborators identified a six-protein panel that provided improved predictive power compared to clinical measures.

The lawsuit, filed in 2015 against Accelerate and some of its executives alleging false and misleading statements, was dismissed after the plaintiffs requested the action.

T2 Biosystems' device will potentially enable 95 percent of patients with bloodstream infections to receive targeted therapy within eight hours of a blood draw.

The collaboration will use T2Dx instruments at Cidara US trial sites to detect sepsis-causing superbugs including Candida auris.   

During a clinical study, a positive antimicrobial stewardship outcome emerged in 74 percent of cases where the firm's test provided a rule-out result for sepsis. 

BioMérieux is deploying consultants to advise hospitals about the most optimal testing options and how to implement them.

As a longer-term product, the firm is developing a sequencing test for the clinic that could enable identifying a broad range of sepsis pathogens and detecting antimicrobial resistance.

Ortho Clinical Diagnostics is developing the assay for use on its Vitros systems for use by small-, mid-, and high-volume labs in managing sepsis.

The financing will go toward efforts by the German firm to bring its point-of-care screening system for drug-resistant bacteria to hospitals. 

The clearance provides clinicians in emergency departments, intensive care, and other hospital units with a tool for antibiotic stewardship.